

Clinical trials of antiplatelets drug for CABG surgery in all type of patients

TrialResults-center www.trialresultscenter.org

1 clopidogrel

Trial	Treatments	Patients	Trials design and methods
clopidogrel+aspirin vs aspirin			
CASCADE , 2009 [NCT00228423] n=56/57 follow-up: 1 y	aspirin 162 mg plus clopidogrel 75 mg daily for 1 year versus aspirin 162 mg plus placebo daily	patients after CABG involving at least two saphenous vein grafts	Parallel groups double blind

References

CASCADE, 2009:

Kulik A, Le May M, Wells GA, Mesana TG, Ruel M The clopidogrel after surgery for coronary artery disease (CASCADE) randomized controlled trial: clopidogrel and aspirin versus aspirin alone after coronary bypass surgery [NCT00228423]. *Curr Control Trials Cardiovasc Med* 2005 Oct 11;6:15 [[16219100](#)]

Kulik A, Le May MR, Voisine P, Tardif JC, Delarochelliere R, Naidoo S, Wells GA, Mesana TG, Ruel M Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. *Circulation* 2010 Dec 21;122:2680-7 [[21135365](#)] [10.1161/CIRCULATIONAHA.110.978007](#)

2 platelet aggregation inhibitors

Trial	Treatments	Patients	Trials design and methods
aspirin + dipyridamol vs control			
Pantely , 1979 n=18/30 follow-up: 6m	aspirin 325 mg three times a day + dipyridamole 75 mg three times a day versus control	patients undergoing aortocoronary saphenous-vein bypass-graft surgery	open
Brussels , 1987 n=24/25 follow-up: 12m	-	-	
Czech , 1986 n=47/46 follow-up: 12m	aspirin 1000 + dipiridamol 225 versus control (no medication)	Patients with aortocoronary bypasses with intraoperative blood flow rates of 40 ml/min or less	open
Des Moines , 1980 n=60/54 follow-up: 12m	-	-	
dipyridamol vs control			

continued...

Trial	Treatments	Patients	Trials design and methods
Toronto dipyridamole , 1987 n=20/20 follow-up: 48h	dipiridamol 400 versus control	patients undergoing elective coronary artery bypass grafting	
sulotroban vs control			
German sulotroban , 1989 n=90/85 follow-up: 21d	-	-	
ticlopidine vs control			
Zurich , 1982 n=50/50 follow-up: 3m	-	-	
Knudsen-B , 1983 n=9/10 follow-up: 6m	-	-	
Romeo , 1983 n=20/20 follow-up: 3m (12m)	-	-	
Kohn , 1990 n=21/24 follow-up: 14d	-	-	
aspirin vs placebo			
McEnany , 1982 n=71/77 follow-up: 22m	aspirin 1200 versus placebo	patients undergoing coronary bypass grafting	double blind
Lorenz , 1984 n=29/31 follow-up: 4m	aspirin 100 mg/d versus placebo	patients undergoing CABG	double blind
GESIC (aspirin) , 1990 n=373/371 follow-up: 28d	aspirin 150 mg daily versus placebo	patients undergoing CABG	Parallel groups double blind
Sydney , 1991 n=127/110 follow-up: 12m	aspirin 324 mg daily versus placebo	patients undergoing CABG	double blind
Hockings , 1993 n=72/72 follow-up: 6m	aspirin 100 versus placebo	patients undergoing CABG	double blind
aspirin + dipyridamol vs placebo			
GESIC (aspirin+dipyridamol) , 1990 n=368/371 follow-up: 28d	aspirin 50 mg + dipyridamole 75mg 3 times daily versus placebo	patients undergoing CABG	Parallel groups double blind Spain

continued...

Trial	Treatments	Patients	Trials design and methods
Brooks , 1985 n=160/160 follow-up: 12m	aspirin 990 mg and dipyridamole 225 mg daily versus placebo	patients undergoing coronary bypass grafting	double blind
Mayo-A , 1984 n=202/205 follow-up: 12m	aspirin 975 + dipyridamol 225 versus placebo	patients undergoing coronary bypass grafting	double blind
Wadsworth , 1985 n=96/102 follow-up: 12m	aspirin 975 mg/d + dipyridamol 225 mg/d, aspirin 975 mg/d versus placebo	coronary bypass patients	double blind
Basel , 1989 n=62/63 follow-up: 9m	aspirin 50 + dipyridamol 400 versus placebo	patients who had aortocoronary vein bypass surgery	double blind
Leeds-B , 1985 n=61/64 follow-up: 6m	aspirin 990 + dipyridamol 225 (W) versus placebo	patients undergoing aorta-coronary bypass grafting for disabling angina	double blind
Thaulow , 1987 n=34/35 follow-up: 3m	aspirin 975 + dipyridamol 225 versus placebo	Patients scheduled to receive at least three aortocoronary venous bypass grafts	double blind
dipyridamol vs placebo			
Ekestrom , 1990 n=174/186 follow-up: 12m	dipyridamol 100 mg orally q.i.d. versus placebo	patients undergoing coronary bypass surgery	double blind
sulfinpyrazone vs placebo			
Baur , 1982 n=130/125 follow-up: 10d	sulfinpyrazone 800 mg/day versus placebo	patients undergoing CABG	double blind
ticlopidine vs placebo			
Lige-I , 1984 n=75/75 follow-up: 3m	ticlopidine 250 mg twice daily versus placebo	patients undergoing aortocoronary bypass graft procedures	double blind
Lige-II , 1987 n=88/87 follow-up: 12m	ticlopidine 250 mg twice daily versus placebo	patients undergoing venous coronary artery bypass grafting	double blind
various vs placebo			
Guiteras , 1989 n=141/69 follow-up: 7m	aspirin 150 + dipyridamol 225, dipyridamol 225 + trifusal 900 versus placebo	patients undergoing coronary bypass grafting	double blind

continued...

Trial	Treatments	Patients	Trials design and methods
VA Co-op CABG , 1988 n=619/153 follow-up: 12m	aspirin 325 daily, aspirin 325 three times daily, sulfipyrazone, aspirin plus dipyridamole (325 mg and 75 mg, respectively, three times daily) versus placebo	patients undergoing CABG	Parallel groups double blind

References

Pantely, 1979:

Pantely GA, Goodnight SH Jr, Rahimtoola SH, Harlan BJ, DeMots H, Calvin L, Rsch J Failure of antiplatelet and anticoagulant therapy to improve patency of grafts after coronary-artery bypass: a controlled, randomized study. N Engl J Med 1979;301:962-6 [386118]

Brussels, 1987:

Lavenne-Pardonge E, Col-de Beys C, Dion R, Ponlot R, Moriau M.A Effect of antiaggregant on occlusion of saphenous graft coronary bypass Thromb Haemost 1987;58:547 (Abstract 2024)

Czech, 1986:

Pirk J, Vojcek J, Kovc J, Fabin J, Firt P Improved patency of the aortocoronary bypass by antithrombotic drugs. Ann Thorac Surg 1986;42:312-4 [3489445]

Des Moines, 1980:

Klotz L Antiplatelet and anticoagulant therapy after coronary bypass. N Engl J Med 1980;302:866 [6965764]

Toronto dipyridamole, 1987:

Teoh KH, Christakis GT, Weisel RD, Madonik MM, Ivanov J, Wong PY, Mee AV, Levitt D, Benak A, Reilly P Blood conservation with membrane oxygenators and dipyridamole. Ann Thorac Surg 1987;44:40-7 [3300583]

German sulotroban, 1989:

Hacker RW, Troka M, Yukseltan I, Pohlmann V, Meier P, Zimmermann T, et al. Reduction of the vein graft occlusion rate after coronary artery bypass surgery by treatment with a thromboxane receptor antagonist. Z Kardiol 1989;78(suppl 3):48-9

Zurich, 1982:

Rothlin ME, Pflger K, Speiser K, Geroulanos SJ, Goebel N, Turina M, et al. Clinical experience with anti-platelet drugs in aorta-coronary bypass surgery Coronary Artery Disease Today 1982;557:413-9

Knudsen-B, 1983:

Mortensen SA, Knudsen JB, Hjelms E, Efsen F. Pre- and post-operative platelet inhibition with ticlopidine in connexion with coronary artery bypass surgery (CABG). Eur Heart J 1983;4 (suppl 3):Abstract 001 F.

Romeo, 1983:

Romeo F, Ruvolo G, Martuscelli E, Comito M, Cardona N, Colistra C, et al. Ticlopidine in the prevention of the block of aorto-coronary by-pass. Proceedings of satellite symposium of 83rd Congress of Italian society of Internal Medicine. Rome: 1982:155-60

Kohn, 1990:

Kohn RN. Study of the safety of perioperative administration of ticlopidine hydrochloride in coronary artery bypass surgery. Eur Heart J 1990;11:186-9 (Sanofi internal report 001.6.186)

McEnany, 1982:

McEnany MT, Salzman EW, Mundth ED, DeSanctis RW, Harthorne JW, Weintraub RM, Gates S, Austen WG The effect of antithrombotic therapy on patency rates of saphenous vein coronary artery bypass grafts. J Thorac Cardiovasc Surg 1982;83:81-9 [7033673]

Lorenz, 1984:

Meister W, von Schacky C, Weber M, Lorenz R, Kotzur J, Reichart B, Theisen K, Weber PC Low-dose acetylsalicylic acid (100 mg/day) after aortocoronary bypass surgery: a placebo-controlled trial. *Br J Clin Pharmacol* 1984;17:703-11 [[6378232](#)]

GESIC (aspirin), 1990:

Sanz G, Pajarn A, Alegra E, Coello I, Cardona M, Fournier JA, Gmez-Recio M, Ruano J, Hidalgo R, Medina A Prevention of early aortocoronary bypass occlusion by low-dose aspirin and dipyridamole. Grupo Espaol para el Seguimiento del Injerto Coronario (GESIC) *Circulation* 1990;82:765-73 [[2203555](#)]

Sydney, 1991:

Gavaghan TP, GebSKI V, Baron DW Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study. *Circulation* 1991;83:1526-33 [[2022014](#)]

Hockings, 1993:

Hockings BE, Ireland MA, Gotch-Martin KF, Taylor RR Placebo-controlled trial of enteric coated aspirin in coronary bypass graft patients. Effect on graft patency. *Med J Aust* 1993;159:376-8 [[8377686](#)]

GESIC (aspirin+dipyridamol), 1990:

Brooks, 1985:

Mayo-A, 1984:

Wadsworth, 1985:

Basel, 1989:

Leeds-B, 1985:

Thaulow, 1987:

Ekestrom, 1990:

Baur, 1982:

Lige-I, 1984:

Lige-II, 1987:

Guiteras, 1989:

VA Co-op CABG, 1988:

3 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.